UNSPSC 51124301: Quinacainol

This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5OX8977NGO, chemically known as 4-quinolinemethanol, 2-(1,1-dimethylethyl)-alpha-(2-(4-piperidinyl)ethyl)- but more generally known as quinacainol, which bears US NIH Compound Identifier 55464. European Medicines Agency schedules Quinacainol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10197MIG.

UNSPSC 51124301 Quinacainol, a Commodity code, encompasses pharmaceutical supplies and medications procured by state and local health agencies, fire departments, and multi-jurisdictional health systems. State and local governments buy these products primarily for emergency medical services, hospital pharmacy systems, and public health programs. The issuing bodies span city fire departments, state health and human services agencies, and regional cooperative purchasing alliances that aggregate demand across multiple states and localities. Work solicited under this code includes supply agreements for injectable medications, over-the-counter pharmaceuticals, and generics distributed through authorized wholesalers to facilities including emergency response teams, hospitals, and government health programs.

Recent activity concentrates in Florida and Minnesota, with emerging state-level procurement in Texas. The City of Tampa's Purchasing Department issued an Invitation for Bid (IFB) in April 2026 for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026) supplying 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg for Tampa Fire Rescue, with an estimated contract value of $40,000 and a five percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued a Request for Proposal (RFP) in January 2026 (Solicitation S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating member jurisdictions through three authorized wholesalers, with award effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission issued a Request for Information in April 2026 (RFI HHS0017013) exploring vendor capabilities for direct-to-manufacturer prescription programs, representing preliminary market research rather than a formal competitive solicitation.